Cardiac Pathways submits Tracking system to FDA:
This article was originally published in Clinica
Cardiac Pathways has filed a 510(k) application with the US FDA to market a range of products based on its Tracking System technology. The system can help visualise the position of multiple electrophysiology catheters in the heart simultaneously, in three-dimensions and in real-time without the aid of fluoroscopy. It consists of a line of diagnostic catheters, which contain ultrasound transducers that triangulate, in real-time, their position within the heart, and a computer system that combines real-time, three-dimensional graphics, displaying catheter images while recording the associated intracardiac electrical signals, said the Sunnyvale, California-based company.
You may also be interested in...
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.